What is Pfizer Inc. share price today?

Pfizer Inc. (PFE) share price today is {{live_price}}.

Can Indians buy Pfizer Inc. shares?

Yes, Indians can invest in the Pfizer Inc. (PFE) from India. With INDmoney, you can buy Pfizer Inc. at 0 brokerage. The step-by-step process is as follows: Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes) Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates. Once funds are transferred successfully, you can buy Pfizer Inc. at zero transaction cost.

How can I buy Pfizer Inc. shares from India?

It is very easy to buy Pfizer Inc. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Pfizer Inc. be purchased?

Yes, you can buy fractional shares of Pfizer Inc. with INDmoney app.

What are the documents required to start investing in Pfizer Inc. stocks?

To start investing in Pfizer Inc., You will need the following documents: Proof of Identification (PAN, Aadhaar etc) Proof of address (Aadhaar, Voter ID etc) These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Pfizer Inc.

Today’s highest price of Pfizer Inc. (PFE) is {{1_rba_end}}. Today’s lowest price of Pfizer Inc. (PFE) is {{1_rba_st}}.

What is today's market capitalisation of Pfizer Inc.

Today's market capitalisation of Pfizer Inc. PFE is 140.9B

What is the 52 Week High and Low Range of Pfizer Inc.

52 Week High {{rba_end}} 52 Week Low {{rba_st}}

How much percentage Pfizer Inc. is down from its 52 Week High?

Pfizer Inc. (PFE) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

How much percentage Pfizer Inc. is up from its 52 Week low?

Pfizer Inc. (PFE) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

What are the historical returns of Pfizer Inc.?

1 Month Returns {{1mr}}% 3 Months Returns {{3mr}}% 1 Year Returns {{1yr}}% 5 Years Returns {{5yr}}%

Who is the Chief Executive Officer (CEO) of Pfizer Inc.

Dr. Albert Bourla D.V.M., Ph.D. is the current Chief Executive Officer (CEO) of Pfizer Inc..

Home>
US Stocks>
Pfizer Inc.

Pfizer Inc. (PFE)

$24.94

-0.16

(-0.64%)▲

Market is closed - opens 8 PM, 21 Nov 2024

Pfizer Inc is a multinational pharmaceutical corporation that produces and develops a wide range of innovative health products.

Performance

$24.66
$25.04
$24.94
1.12%
Downside
Day's Volatility :1.52%
Upside
0.4%
$24.48
$31.54
$24.94
1.84%
Downside
52 Weeks Volatility :22.38%
Upside
20.93%

Returns

Period	Pfizer Inc.	Sector (Health Care)	S&P500
3 Months	-13.15%	-8.6%	5.7%
6 Months	-12.02%	-3.3%	11.5%
1 Year	-16.28%	9.4%	30.1%
3 Years	-50.98%	6.2%	25.9%

Highlights

Market Capitalization	140.9B
Book Value	$16.29
Dividend Share	1.67
Dividend Yield	6.77%
Earnings Per Share (EPS)	0.75
PE Ratio	33.15
PEG Ratio	0.17
Wall Street Target Price	32.548

Profit Margin	7.16%
Operating Margin TTM	32.99%

Return On Assets TTM	3.31%
Return On Equity TTM	4.54%

Revenue TTM	59.4B
Revenue Per Share TTM	10.49
Quarterly Revenue Growth YOY	31.2%
Gross Profit TTM	66.2B
EBITDA	18.4B
Diluted Eps TTM	0.75
Quarterly Earnings Growth YOY	-0.98

EPS Estimate Current Year	2.93
EPS Estimate Next Year	2.9
EPS Estimate Current Quarter	0.62
EPS Estimate Next Quarter	0.66

Analyst Recommendation

Hold

43%Buy

56%Hold

0%Sell

Based on 30 Wall street analysts offering stock ratings for Pfizer Inc.(by analysts ranked 0 to 5 stars)

Based on 30 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast

What analysts predicted

Upside of 30.51%

Current $24.94

Target $32.55

Company Financials

	FY18	Y/Y Change
Revenue	53.6B	↑ 2.1%
Net Income	11.2B	↓ 47.66%
Net Profit Margin	20.79%	↓ 19.76%

	FY19	Y/Y Change
Revenue	51.8B	↓ 3.54%
Net Income	16.3B	↑ 45.91%
Net Profit Margin	31.45%	↑ 10.66%

	FY20	Y/Y Change
Revenue	41.9B	↓ 19.02%
Net Income	7.0B	↓ 56.86%
Net Profit Margin	16.75%	↓ 14.7%

	FY21	Y/Y Change
Revenue	81.3B	↑ 93.97%
Net Income	22.0B	↑ 213.09%
Net Profit Margin	27.04%	↑ 10.29%

	FY22	Y/Y Change
Revenue	100.3B	↑ 23.43%
Net Income	31.4B	↑ 42.74%
Net Profit Margin	31.27%	↑ 4.23%

	FY23	Y/Y Change
Revenue	58.5B	↓ 41.7%
Net Income	2.1B	↓ 93.25%
Net Profit Margin	3.62%	↓ 27.65%

	Q2 FY23	Q/Q Change
Revenue	12.7B	↓ 30.35%
Net Income	2.3B	↓ 58.02%
Net Profit Margin	18.27%	↓ 12.05%

	Q3 FY23	Q/Q Change
Revenue	13.2B	↑ 3.91%
Net Income	-2.4B	↓ 202.88%
Net Profit Margin	-18.09%	↓ 36.36%

	Q4 FY23	Q/Q Change
Revenue	14.2B	↑ 7.69%
Net Income	-3.3B	↑ 39.68%
Net Profit Margin	-23.47%	↓ 5.38%

	Q1 FY24	Q/Q Change
Revenue	14.9B	↑ 4.42%
Net Income	3.1B	↓ 193.15%
Net Profit Margin	20.94%	↑ 44.41%

	Q2 FY24	Q/Q Change
Revenue	13.3B	↓ 10.73%
Net Income	24.0M	↓ 99.23%
Net Profit Margin	0.18%	↓ 20.76%

	Q3 FY24	Q/Q Change
Revenue	17.7B	↑ 33.27%
Net Income	4.5B	↑ 18504.17%
Net Profit Margin	25.22%	↑ 25.04%

	FY18	Y/Y Change
Total Assets	159.4B	↓ 7.2%
Total Liabilities	95.7B	↓ 4.47%

	FY19	Y/Y Change
Total Assets	167.5B	↑ 5.06%
Total Liabilities	104.0B	↑ 8.76%

	FY20	Y/Y Change
Total Assets	154.2B	↓ 7.92%
Total Liabilities	90.8B	↓ 12.77%

	FY21	Y/Y Change
Total Assets	181.5B	↑ 17.67%
Total Liabilities	104.0B	↑ 14.61%

	FY22	Y/Y Change
Total Assets	197.2B	↑ 8.67%
Total Liabilities	101.3B	↓ 2.62%

	FY23	Y/Y Change
Total Assets	226.5B	↑ 14.86%
Total Liabilities	137.2B	↑ 35.47%

	Q2 FY23	Q/Q Change
Total Assets	220.2B	↑ 12.55%
Total Liabilities	120.9B	↑ 28.07%

	Q3 FY23	Q/Q Change
Total Assets	215.0B	↓ 2.34%
Total Liabilities	117.8B	↓ 2.53%

	Q4 FY23	Q/Q Change
Total Assets	226.5B	↑ 5.34%
Total Liabilities	137.2B	↑ 16.46%

	Q1 FY24	Q/Q Change
Total Assets	221.1B	↓ 2.39%
Total Liabilities	128.5B	↓ 6.32%

	Q2 FY24	Q/Q Change
Total Assets	216.2B	↓ 2.22%
Total Liabilities	128.2B	↓ 0.25%

	Q3 FY24	Q/Q Change
Total Assets	219.5B	↑ 1.52%
Total Liabilities	126.9B	↓ 1.01%

	FY18	Y/Y Change
Operating Cash Flow	15.8B	↓ 3.9%
Investing Cash Flow	4.5B	↓ 195.44%
Financing Cash Flow	-20.4B	↑ 56.82%

	FY19	Y/Y Change
Operating Cash Flow	12.6B	↓ 20.47%
Investing Cash Flow	-3.9B	↓ 187.18%
Financing Cash Flow	-8.5B	↓ 58.49%

	FY20	Y/Y Change
Operating Cash Flow	14.4B	↑ 14.42%
Investing Cash Flow	-4.3B	↑ 8.26%
Financing Cash Flow	-9.6B	↑ 13.72%

	FY21	Y/Y Change
Operating Cash Flow	32.6B	↑ 126.2%
Investing Cash Flow	-22.5B	↑ 427.89%
Financing Cash Flow	-9.8B	↑ 1.73%

	FY22	Y/Y Change
Operating Cash Flow	29.3B	↓ 10.17%
Investing Cash Flow	-15.8B	↓ 30.0%
Financing Cash Flow	-14.8B	↑ 51.12%

	FY23	Y/Y Change
Operating Cash Flow	8.7B	↓ 70.27%
Investing Cash Flow	-32.3B	↑ 104.51%
Financing Cash Flow	26.1B	↓ 275.72%

	Q2 FY23	Q/Q Change
Operating Cash Flow	-1.2B	↓ 199.67%
Investing Cash Flow	-25.5B	↓ 868.78%
Financing Cash Flow	27.2B	↓ 1080.66%

	Q3 FY23	Q/Q Change
Operating Cash Flow	3.5B	↓ 386.09%
Investing Cash Flow	888.0M	↓ 103.48%
Financing Cash Flow	-3.8B	↓ 113.91%

	Q4 FY23	Q/Q Change
Operating Cash Flow	5.2B	↑ 51.62%
Investing Cash Flow	-11.0B	↓ 1338.29%
Financing Cash Flow	5.4B	↓ 244.01%

	Q1 FY24	Q/Q Change
Operating Cash Flow	1.1B	↓ 79.18%
Investing Cash Flow	1.7B	↓ 115.75%
Financing Cash Flow	-4.9B	↓ 190.61%

Technicals Summary

Sell

Neutral

Buy

Pfizer Inc. is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Pfizer Inc.	-13.24%	-12.02%	-16.28%	-50.98%	-32.25%
Procter & Gamble Company, The	0.72%	2.06%	13.64%	15.53%	39.64%
Johnson & Johnson	-6.04%	1.14%	2.06%	-4.2%	12.55%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Pfizer Inc.	33.15	33.15	0.17	2.93	0.05	0.03	0.07	16.29
Procter & Gamble Company, The	29.39	29.39	3.6	6.55	0.29	0.11	0.02	21.68
Johnson & Johnson	25.45	25.45	0.92	9.96	0.21	0.08	0.03	29.14

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Pfizer Inc.	Hold	$140.9B	-32.25%	33.15	7.16%
Procter & Gamble Company, The	Buy	$402.1B	39.64%	29.39	17.06%
Johnson & Johnson	Buy	$370.8B	12.55%	25.45	16.74%

Insights on Pfizer Inc.

Increasing Revenue
Revenue is up for the last 2 quarters, 13.28B → 17.70B (in $), with an average increase of 25.0% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 24.0M → 4.46B (in $), with an average increase of 99.5% per quarter
Vs PG
In the last 1 year, Procter & Gamble Company, The has given 13.6% return, outperforming this stock by 29.9%
Vs PG
In the last 3 years, Procter & Gamble Company, The has given 16.3% return, outperforming this stock by 66.9%

Institutional Holdings

Vanguard Group Inc
9.11%
BlackRock Inc
7.49%
State Street Corp
5.07%
Wellington Management Company LLP
2.93%
Morgan Stanley - Brokerage Accounts
2.73%
Charles Schwab Investment Management Inc
2.30%

Corporate Announcements

Pfizer Inc. Dividends March,2024
In the quarter ending March,2024. Pfizer Inc. has declared dividend of $0.42
Read More

Organization	Pfizer Inc.
Employees	88000
CEO	Dr. Albert Bourla D.V.M., Ph.D.
Industry	Health Technology

Pfizer Inc. (PFE)

Performance

Returns

Highlights

Analyst Recommendation

Analyst Forecast

Company Financials

Technicals Summary

Peers

Increasing Revenue

Increasing Net Profit

Vs PG

Vs PG

Institutional Holdings

Corporate Announcements

Pfizer Inc. Dividends March,2024

Company Information

Discover More

FAQs